HGS/GSK's Benlysta Gets Advisory Panel Backing For Lupus Labeling That Reflects Trials' Limitations
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee says belimumab efficacy is not shown for full spectrum of the disease, so the biologic should go to market with appropriate caveats.